Top

Published in:

Open Access 01-12-2012 | Research article

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients

Authors: Maike Ihnen, Kerstin Kress, Jan Felix Kersten, Ergin Kilic, Matthias Choschzick, Hilke Zander, Volkmar Müller, Sven Mahner, Fritz Jänicke, Linn Woelber, Karin Milde-Langosch

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

An altered expression of the activated leukocyte cell adhesion molecule (ALCAM) is associated with cancer progression in various cancer types. In some cancers ALCAM has a prognostic value or is predictive for the benefit of therapeutic interventions. To date there are no data on the role of ALCAM in cervical cancer available.

Methods

In this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233 patients with cervical cancer, among them 178 with complete follow-up information. In addition, soluble (s-)ALCAM was measured in sera of a subset of the included patients (n = 55) by enzyme-linked immunosorbent assay (ELISA).

Results

ALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer samples. The normal ectocervical or endocervical epithelium showed no ALCAM reactivity. In untreated patients, ALCAM overexpression in tumor tissue tended to be associated with shorter cancer-specific survival (CSS) and disease-free survival (DFS). Patients, whose tumor samples showed ALCAM overexpression receiving a cytotoxic therapy like radiotherapy or chemoradiation, however, had a favourable prognosis compared to those patients, whose cancers showed no or minimal ALCAM staining. This effect was particularly apparent in patients receiving chemoradiation where the CSS was significantly longer in patients with ALCAM-positive tumors (p = 0.038; cumulative incidence rates at 96 months 8%, 95% CI 0%-23%, and 26%, CI 3%-43% in ALCAM-positive and ALCAM-negative cases, respectively).

Median preoperative s-ALCAM concentration in sera from tumor patients was 27.6 ng/ml (range 17.5-55.1 ng/ml, mean 28.9 ng/ml), serum levels did not correlate with intratumoral ALCAM expression.

Conclusions

The data of our retrospective study suggest that the prognostic value of ALCAM expression in cervical carcinoma might be therapy-dependent, and that ALCAM might function as a predictive marker for the response to chemoradiation. This should be confirmed in further, prospective studies.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008, 127: 2893-2917.CrossRef

Rosa DD, Medeiros LR, Edelweiss MI, Bozzetti MC, Pohlmann PR, Stein AT, Dickinson HO: Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2009, CD005342-3

van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, Figdor CG, Swart GW: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 2001, 276: 25783-25790. 10.1074/jbc.M011272200.CrossRefPubMed

Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007, 104: 10158-10163. 10.1073/pnas.0703478104.CrossRefPubMedPubMedCentral

van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000, 156: 769-774. 10.1016/S0002-9440(10)64943-7.CrossRefPubMedPubMedCentral

Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate. 2003, 54: 34-43. 10.1002/pros.10161.CrossRefPubMed

Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004, 57: 1160-1164. 10.1136/jcp.2004.016238.CrossRefPubMedPubMedCentral

Ofori-Acquah SF, King JA: Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008, 151: 122-128. 10.1016/j.trsl.2007.09.006.CrossRefPubMed

King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG: Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 2004, 6: R478-R487. 10.1186/bcr815.CrossRefPubMedPubMedCentral

10.

van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ, van Kempen LC: Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol. 2010, 46: 393-398. 10.1016/j.oraloncology.2010.03.001.CrossRefPubMed

11.

Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R: MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology. 2005, 68: 462-470. 10.1159/000086989.CrossRefPubMed

12.

Ihnen M, Muller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F, Milde-Langosch K: Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008, 112: 419-427. 10.1007/s10549-007-9879-y.CrossRefPubMed

13.

Hong X, Michalski CW, Kong B, Zhang W, Raggi MC, Sauliunaite D, De Oliveira T, Friess H, Kleeff J: ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. J Surg Oncol. 2010, 101: 564-569. 10.1002/jso.21538.CrossRefPubMed

14.

Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M: The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res. 2007, 5: 1246-1253. 10.1158/1541-7786.MCR-07-0060.CrossRefPubMed

15.

Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP: Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. Int J Cancer. 2009, 125 (1): 9-14. 10.1002/ijc.24292.CrossRefPubMedPubMedCentral

16.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006, 100: 229-235. 10.1007/s10549-006-9242-8.CrossRefPubMed

17.

Remmele W, Stegner H-E: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-140.PubMed

18.

Woelber L, Kress K, Kersten JF, Choschzick M, Kilic E, Herwig U, Lindner C, Schwarz J, Jaenicke F, Mahner S, Milde-Langosch K, Mueller V, Ihnen M: Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer. 2011, 11: 12-10.1186/1471-2407-11-12.CrossRefPubMedPubMedCentral

19.

Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G: Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006, 59: 403-409. 10.1136/jcp.2005.028209.CrossRefPubMedPubMedCentral

20.

Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S: Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res. 2008, 14: 1726-1733. 10.1158/1078-0432.CCR-07-0428.CrossRefPubMed

21.

Sawhney M, Matta A, Macha MA, Kaur J, DattaGupta S, Shukla NK, Ralhan R: Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer. 2009, 124: 2098-2105. 10.1002/ijc.24192.CrossRefPubMed

22.

Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, Koch M, Aigner M, Weitz J: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 2009, 101: 457-464. 10.1038/sj.bjc.6605136.CrossRefPubMedPubMedCentral

23.

Ishigami S, Ueno S, Arigami T, Arima H, Uchikado Y, Kita Y, Sasaki K, Nishizono Y, Omoto I, Kurahara H, Matsumoto M, Kijima Y, Natsugoe S: Clinical implication of CD166 expression in gastric cancer. J Surg Oncol. 2010, 103: 57-61.CrossRef

24.

Corrias MV, Gambini C, Gregorio A, Croce M, Barisione G, Cossu C, Rossello A, Ferrini S, Fabbi M: Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse. Cell Oncol. 2010, 32: 77-86.PubMedPubMedCentral

25.

Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K: Biological role of Activated Leukocyte Cell Adhesion Molecule (ALCAM) overexpression in breast cancer cell lines and clinical tumour tissue. Breast Cancer Res Treatm. 2011, 129 (2): 347-360. 10.1007/s10549-010-1219-y.CrossRef

26.

Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, Sauter G, Pantel K, Izbicki JR, Bockhorn M: ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer. 2011, doi: 10.1002/ijc.26377.

27.

Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung TH, Lo KW, Yim SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina E, McKinnon RD, Denhardt DT, Chin KV, Chung TK: Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res. 2003, 9: 5486-5492.PubMed

28.

Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, Nakamura Y, Katagiri T: Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004, 60: 237-248. 10.1016/j.ijrobp.2004.02.047.CrossRefPubMed

29.

Rajkumar T, Vijayalakshmi N, Sabitha K, Shirley S, Selvaluxmy G, Bose MV, Nambaru L: A 7 gene expression score predicts for radiation response in cancer cervix. BMC Cancer. 2009, 9: 365-10.1186/1471-2407-9-365.CrossRefPubMedPubMedCentral

30.

Blaheta RA, Daher FH, Michaelis M, Hasenberg C, Weich EM, Jonas D, Kotchetkov R, Doerr HW, Cinatl J: Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer. 2006, 6: 294-10.1186/1471-2407-6-294.CrossRefPubMedPubMedCentral

31.

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007, 31: 277-283.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/140/prepub

Title: Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
Authors: Maike Ihnen
Kerstin Kress
Jan Felix Kersten
Ergin Kilic
Matthias Choschzick
Hilke Zander
Volkmar Müller
Sven Mahner
Fritz Jänicke
Linn Woelber
Karin Milde-Langosch
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-140

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study

Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

Hepatitis B virus X protein suppresses caveolin-1 expression in hepatocellular carcinoma by regulating DNA methylation

An association between hOGG1Ser326Cys polymorphism and the risk of bladder cancer in non-smokers: a meta-analysis

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer